← Compound index
COMPOUND RECORD / VESUGEN

VesugenВезуген

RecoveryPerformance
Source linked
Research profile — evidence review incomplete. Topic tags are research navigation, not indications or recommendations. Source access does not establish effectiveness or safety.
01 / OVERVIEW

What is it?

A short peptide containing three amino acids, listed in the 2013 bioregulator catalogue in connection with vascular function. This is a research target, not an established treatment benefit.

Identity / background source ↗

Research context

The occupational report names Pinealon and Vezugen in combination. The accessible abstract does not isolate Vesugen’s contribution or establish safer driving.

Working classification
Bioregulator
Research collection
Peptide bioregulation · editorial grouping
Institutional provenance
Not established for this compound record
Last evidence review
Full evidence review pending; source-check scope appears with each publication below.
02 / EVIDENCE DIMENSIONS

What do we know?

Human research
—Combination report
Study methods
—Abstract-level review
Independent replication
—Not assessed
Source access
—English abstract
Safety evidence
—Not assessed

These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.

03 / SOURCE TRAIL

Linked sources

Explore the research map and unresolved leads ↗

2013ReviewFull text available

Mechanism of Biological Activity of Short Peptides: Cell Penetration and Epigenetic Regulation of Gene Expression

V. Kh. Khavinson, A. Yu. Solovyev, S. I. Tarnovskaya, N. S. Linkova · Biology Bulletin Reviews 3(6):451–455

Mechanistic review with a table of 15 short peptides on page 453. Tissue labels in the research map are the authors’ proposed targets, not established clinical indications.

Population / setting
Review of earlier research
What was checked
Author-hosted English PDF and its peptide table checked. Each cited experiment remains a separate appraisal task.
Limitations & review scope
  • Source-linked does not mean a completed risk-of-bias review.
  • A review is not an independent clinical replication; proposed mechanisms do not establish efficacy or safety.

Source checked 2026-09-27. This is a source-linked record, not a completed evidence review.

Read the source ↗
2012Human comparative studyEnglish abstract

The peptide correction of neurotic disorders among professional truck-drivers

A. S. Bashkireva, V. G. Artamonova · Adv Gerontol. 25(4):718–728

The abstract describes occupational psychoemotional differences and reports changes with peptide bioregulators, including combined Pinealon and Vezugen.

Population / setting
150 male lorry drivers and 150 male metal craftsmen in the occupational comparison
What was checked
PubMed record and English abstract checked; intervention allocation and full methods not reviewed.
Limitations & review scope
  • The occupational cohort size is not a verified randomized-treatment sample size.
  • Randomization, blinding, and intervention-group sizes are not established from the abstract.
  • Combination findings do not identify either peptide’s independent contribution or demonstrate fewer driving accidents.

Source checked 2026-09-27. This is a source-linked record, not a completed evidence review.

Read the source ↗

Explore related historical combinations ↗

Browse bibliography & PDFs ↗